The type 1 diabetes genetic risk score, or T1D-GRS, is a tool that has already proven its worth in diabetes prediction and classification. It aggregates information from ten single nucleotide polymorphisms, or SNPs—individual positions in the genome where the DNA letter varies between people and where certain variants shift the probability of developing the autoimmune form of diabetes. Because the score draws on genetic variants that remain stable throughout life, it can help distinguish type 1 from type 2 diabetes in young adults and identify individuals at elevated risk long before symptoms appear. Crucially, the T1D-GRS and islet autoantibodies, the immune markers that signal the body’s attack on insulin-producing cells, act as independent predictors of diabetes, which makes pairing them particularly powerful for screening and diagnostic purposes.

The obstacle has always been practical rather than scientific. To calculate the score, laboratories traditionally need genomic DNA extracted from white blood cells, which involves purification, quantification and storage steps that add expense at every turn, before a single genotyping reaction has even been set up. The Exeter team reasoned that this entire pipeline might be unnecessary. Serum, the very material already used for islet autoantibody assays, contains extracellular DNA released from cells that burst during the clotting process. If that DNA were sufficient for genotyping, the same tube of blood could serve both the antibody test and the genetic score, eliminating the need for a separate DNA extraction altogether.

There was a catch, however, and it lay in the biochemistry of clotting. The extracellular DNA in serum comes from leukocytes that rupture as the blood clots, so the amount of genomic DNA available depends on how long the sample is allowed to clot before being spun down in a centrifuge. Many standard serum processing protocols specify clotting times of less than thirty minutes, a window that previous work suggested may be inadequate for releasing enough genomic DNA into the fluid. The researchers therefore designed their study to answer two linked questions: whether a direct-from-serum genotyping method could calculate the ten-SNP T1D-GRS accurately, and how strongly the answer depended on clotting time.

The technical setup was deliberately conventional, which is part of the method’s appeal. The team used TaqMan SNP genotyping assays, a widely adopted fluorescence-based qPCR chemistry, together with TaqPath ProAmp Master Mix, in tiny five-microliter reactions containing just one microliter of either purified DNA or raw serum. Plates, prepared on a Biomek i7 Automated Workstation and run for fifty cycles on a QuantStudio 12K Flex Real-Time PCR System, included positive and no-template controls, and genotypes were called automatically using commercial software. In other words, nothing exotic was required—only standard reagents, standard instruments and a single microliter of serum per SNP.

Accuracy came first. In a cohort of 116 matched serum and whole-blood-derived DNA samples sent to the Exeter Genomics Laboratory from across the UK and Ireland, all with clotting times exceeding 24 hours, both biospecimens achieved call rates above 95 percent across all ten SNPs on the first pass, with no repeated reactions. A complete T1D-GRS was obtained from 84.5 percent of serum samples compared with 96.6 percent of purified DNA samples, a statistically significant difference, but among the 94 samples where both approaches yielded a complete score, the results agreed perfectly—100 percent concordance. In a subset of 32 samples with sequencing data available, the serum-derived scores were again fully concordant, confirming that the shortcut does not come at the cost of correctness.

The clotting-time experiment revealed where the method’s limits lie. The team analyzed 122 serum samples with recorded clotting times ranging from 12 to 475 minutes, running every sample in duplicate on separate qPCR runs to check reproducibility. Splitting the cohort at the thirty-minute mark produced a striking contrast. Samples clotted for thirty minutes or less achieved a genotyping success rate of just 68.8 percent, a replicate discordance rate of 28.8 percent, and yielded a complete ten-SNP score in only 7.4 percent of cases. Samples clotted for longer than thirty minutes, by comparison, reached a 97 percent genotyping success rate, only 2.2 percent replicate discordance, and complete scores in 77.8 percent of samples—a difference the authors report as highly significant. Performance in this longer-clotting group closely matched that of the samples clotted for more than 24 hours.

The explanation, the researchers argue, is straightforward: insufficient clotting time leaves too little extracellular DNA in the serum for reliable amplification. This aligns with earlier findings that PCR-based genotyping from samples containing very low DNA concentrations—below roughly 56 picograms—is unreliable. The practical message for laboratories hoping to combine genetic and biochemical testing is that serum should be allowed to clot for more than thirty minutes before processing, a duration that does not compromise autoantibody assays. Where additional tests sensitive to proteolysis, glycolysis or other degradation processes are needed, the authors suggest an intermediate clotting window of more than thirty minutes but under about three hours may offer the optimal balance between DNA release and analyte preservation.

The implications extend well beyond the immediate assay. A direct-from-serum approach could unlock cost-effective genotyping in the many large frozen serum biobanks around the world where no extracted DNA exists, allowing researchers to mine decades of stored samples for genetic risk information without retrieving new blood draws. Although the study tested only ten SNPs, the low input volume of one microliter per SNP suggests the same logic could scale to larger genotyping panels or alternative genotyping chemistries. For clinical laboratories that lack DNA-extraction capability, the proof-of-principle result points toward direct, automated assays that run antibody and genetic tests in parallel from a single serum sample. The work was supported by the National Institute for Health and Care Research Exeter Biomedical Research Centre, and the authors note existing research funding and licensing arrangements with Randox Laboratories to develop a T1D-GRS assay, underscoring the translational momentum behind the approach. If the method holds up in broader validation, the humble serum tube—already the workhorse of clinical chemistry—may become a one-stop source for both immune and genetic markers of diabetes risk.

Subject of Research: A direct-from-serum genotyping method for calculating a type 1 diabetes genetic risk score

Article Title: A direct-from-serum method for calculating a type 1 diabetes genetic risk score

Article References: Spurrier, B., Oram, R. A., Thomas, N. J., & Locke, J. M. (2026). A direct-from-serum method for calculating a type 1 diabetes genetic risk score. Journal of Translational Medicine, 24(1), Article 1148. https://doi.org/10.1186/s12967-026-08930-4

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08930-4

Keywords: type 1 diabetes, genetic risk score, serum, genotyping, TaqMan, qPCR, SNP, islet autoantibodies, DNA extraction, clotting time, biobanks, precision medicine

The study, published in BMC Genomics by Aitor Almanza of Navarrabiomed and colleagues, addresses a gap that has widened as genomic medicine has scaled up. Next-generation sequencing has transformed precision medicine, but the analytical workflows behind it have become increasingly complex, involving multiple extraction steps, library preparations, batching events and platform transfers. Each handoff is an opportunity for error. While the frequency of sample misidentification may be low, the researchers note that the potential negative outcomes are worrying, particularly in clinical contexts where a wrong sample match can influence diagnosis or treatment decisions. Existing SNP-based quality control solutions, they argue, tend to rely on non-coding genetic markers or require advanced technologies that many laboratories do not have, leaving a need for small, robust panels that are portable across technologies, compatible with diagnostic panels, applicable across diverse populations and straightforward to implement in a wet lab.

The core idea behind the new panel is elegantly simple. Every person carries millions of genetic variants, and the specific combination of variants at a carefully chosen set of positions acts like a molecular fingerprint that is essentially unique to an individual. If a laboratory genotypes those positions in a sample at the start of a workflow and again at the end, or compares a sequencing result against a reference profile collected earlier, any mismatch immediately flags a possible sample swap or contamination. The challenge lies in choosing which variants to include. The markers must be highly discriminant, meaning that the chance of two unrelated people sharing the same profile is vanishingly small. They must also be compatible across platforms, so that a profile generated on a sequencer can be compared with one generated on a qPCR machine, and they must work reliably in populations around the world rather than being calibrated to a single ancestry group.

To build the panel, the team applied a stringent filtering pipeline designed to identify highly discriminant, cross-platform compatible genetic markers supported by predesigned TaqMan assays. TaqMan assays are a widely used qPCR genotyping chemistry in which fluorescent probes report which allele is present at a specific position, making the technology a staple of clinical molecular laboratories. By restricting the candidate markers to SNPs that already have validated, commercially available TaqMan assays, the researchers ensured that any laboratory with standard qPCR infrastructure could adopt the barcode without developing new reagents from scratch. They also prioritized SNPs that are already present in clinical sequencing panels, a decision with important practical consequences: it means the barcode can often be read directly from data that clinical laboratories are already generating, without any additional sequencing effort.

Population applicability was a central design criterion. A barcode that discriminates well in European populations but poorly in East Asian or African populations would be of limited use in the diverse patient cohorts of modern medicine. The researchers therefore prioritized markers with broad applicability across world populations, drawing on allele frequency data to ensure that the panel retains its discriminatory power regardless of the ancestry of the person being tested. This focus distinguishes the panel from earlier identity-testing approaches that were often optimized for specific populations or that relied on markers whose behavior across ancestries was less well characterized. The result is a barcode intended to be genuinely portable, both technologically and demographically.

The validation of the panel drew on the NAGENDATA cohort, a collection of neuropathology samples from Navarra, Spain, gathered under informed consent for research use and approved by the Research Ethics Committee of Navarra. The team used whole-genome sequencing data from 150 samples in the cohort to establish reference profiles and then cross-validated the barcode with qPCR genotyping. The numbers reported are striking. The full 44-SNP panel demonstrates exceptional discriminatory power, with theoretical cumulative random match probabilities ranging from 2.43 times ten to the power of minus nineteen in European populations to 9.37 times ten to the power of minus eighteen in East Asian populations. In plain terms, the probability that two unrelated individuals share the same 44-SNP profile is so small, on the order of one in many quintillions, that a matching profile can be treated as conclusive evidence of identity for practical purposes.

Cross-platform performance is where the panel earns its clinical credentials. When the researchers compared profiles generated by next-generation sequencing with those generated by qPCR, they found 99 percent concordance between the two technologies. That level of agreement matters because the whole point of a portable barcode is that a profile generated in one laboratory, on one instrument, can be trusted when compared against a profile generated elsewhere, on a different instrument, perhaps years later. A barcode that produced different answers depending on the platform would generate false alarms and erode confidence. The high concordance indicates that the selected SNPs genotype cleanly and consistently across chemistries, a property that reflects careful marker selection as much as analytical rigor.

The panel did not merely perform well in theory; it caught real errors. Combined within-platform and cross-platform analyses successfully identified three cases of sample mislabelling in the NAGENDATA collection. Those three detections, in a cohort of 150 samples, illustrate the kind of silent failures that can lurk in even well-managed biobanks and sequencing facilities. Without an independent genetic check, such mislabelled samples would have propagated through downstream analyses, potentially associating genomic data with the wrong individual and contaminating scientific conclusions. In a clinical workflow, the same failure could have far more serious consequences. The demonstration that a compact barcode can surface these errors retroactively, using data already on hand, underscores the practical value of the approach.

The researchers describe the result as a robust, ready-to-deploy SNP barcode that bridges next-generation sequencing and wet-lab workflows, enabling retrospective sample authentication across sequencing platforms and qPCR systems. The retrospective dimension deserves emphasis. Because many clinical sequencing panels already include the barcode SNPs, laboratories can often authenticate historical samples by extracting the relevant positions from existing sequencing files and comparing them against qPCR profiles or against other sequencing data. This opens the door to auditing past datasets for sample integrity issues without re-extracting DNA or re-running expensive assays, a capability that could be valuable for quality assurance programs, biobank certification and the growing movement toward reproducibility in genomics.

The design choices also reflect the regulatory and economic realities of clinical genomics. Sample tracking and data integrity sit at the intersection of privacy frameworks such as the GDPR and HIPAA, and laboratories need solutions that protect patient identity while verifying it. A 44-SNP barcode is deliberately minimal: it contains far too little information to reconstruct a person’s appearance, health risks or ancestry in any meaningful detail, yet more than enough to distinguish one individual from another. Combined with cost-effective implementation on equipment that most molecular laboratories already own, the panel lowers the barrier to routine sample authentication. As sequencing becomes ever more embedded in research and clinical routine, tools like this barcode point toward a future where every genomic dataset carries an internal, verifiable proof of its own provenance, quietly guarding against the swapped tubes and mislabelled plates that no laboratory is immune to.

Subject of Research: A TaqMan-compatible 44-SNP panel for cross-platform genetic sample authentication and tracking

Article Title: A TaqMan-compatible 44-SNP barcode for robust sample tracking in research and clinical settings

Article References: A TaqMan-compatible 44-SNP barcode for robust sample tracking in research and clinical settings. (n.d.). https://doi.org/10.1186/s12864-026-13282-w

Image Credits: AI Generated

DOI: 10.1186/s12864-026-13282-w

Keywords: sample tracking, SNP barcode, TaqMan, genomics, next-generation sequencing, qPCR, whole-genome sequencing, biobank, data integrity, precision medicine, sample mislabelling, genotyping